Latest news

• GSK’s shingles vaccine Shingrix claims US approval

  Becomes first alternative to Merck &Co’s Zostavax. GlaxoSmithKline has picked up its second approval for new shingles vaccine Shingrix, a potential blockbuster that is considered key to the company’s ... The FDA has approved Shingrix for the

• GSK's Shingrix sails through FDA advisory committee

  It is increasingly common with advancing age. GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which remain ... In June, the company reported the results of a trial

• GSK makes case for revaccination with Shingrix

  The results of the Zoster-048 study met its primary objective of showing that people who had received the currently-approved vaccine - Merck &Co's Zostavax - at least five years previously ... after clinical data demonstrated the drug's greater efficacy

• GSK files shingles vaccine Shingrix in Europe

  Blockbuster hopeful would compete with Merck &Co’s Zostavax.  . GlaxoSmithKline has submitted its shingles vaccine Shingrix for European marketing authorisation, following on the heels of its FDA filing last month. ... By contrast, Zostavax -

• GSK's blockbuster hopeful Shingrix filed in US

  In contrast, Zostavax' efficacy is generally between 18% and 70% and is known to decline in older people. ... GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which